Alpha Tau Medical
DRTS
12 hedge funds and large institutions have $5.28M invested in Alpha Tau Medical in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.63% more ownership
Funds ownership: 0% → 1.63% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.63M |
| 2 |
Barclays
London,
United Kingdom
|
+$914K |
| 3 |
Capstone Investment Advisors
New York
|
+$187K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$184K |
| 5 |
E
Ergoteles
New York
|
+$146K |
Top Sellers
DRTS Hedge Fund Activity: Q1 2022 in Review
12 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Alpha Tau Medical (DRTS) for Q1 2022, worth a combined $5.28M.
Buyers outnumbered sellers: 12 funds opened new DRTS positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $3.63M.
- 12 institutional investors held Alpha Tau Medical (DRTS) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $5.28M of Alpha Tau Medical stock for Q1 2022.
- 12 funds opened new Alpha Tau Medical positions in Q1 2022 and 0 closed out, a net change of +12 holders.
- The largest Alpha Tau Medical buyer in Q1 2022 was Fidelity Investments, an estimated $3.63M added.
Based on aggregated 13F filings for Q1 2022.